Envestnet Asset Management
CYTO

Envestnet Asset Management’s Altamira Therapeutics Ltd CYTO Stock Holding History

Envestnet Asset Management’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50
Closed -$69K – 3717
2021
Q1 		$69K Buy
50
+19
+61% +$25.5K ﹤0.01% 3442
2020
Q4 		$33K Buy
+31
New +$19.9K ﹤0.01% 3245

Other funds holding CYTO

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Envestnet Asset Management's CYTO Position: Q2 2021 in Review

Envestnet Asset Management sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2021, closing a stake of 50 shares — an estimated $69K sold.

Envestnet Asset Management first reported a position in CYTO in Q4 2020 and held it in 2 quarters. The position peaked at $69K in Q1 2021. 11 funds tracked by Wall St. Rank hold CYTO as of Q2 2021.

  • Envestnet Asset Management reported no remaining Altamira Therapeutics Ltd position as of Q2 2021 after selling out during the quarter.
  • Envestnet Asset Management sold 50 Altamira Therapeutics Ltd shares in Q2 2021, an estimated $69K.
  • Envestnet Asset Management first reported a position in Altamira Therapeutics Ltd in Q4 2020 and held it in 2 quarters.
  • Envestnet Asset Management's Altamira Therapeutics Ltd position peaked at $69K in Q1 2021.
  • 11 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2021.

Based on Envestnet Asset Management's 13F filing for Q2 2021, filed 4 Aug 2021.